Cytokinetics Stock News

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...

SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2020 at 4:00

SOUTH SAN FRANCISCO, Calif., July 21, 2020 -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of.

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of 8,385,41

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Cytokinetics (NASDAQ:CYTK) had its target price boosted by JMP Securities from $23.00 to $29.00 in a report published on Wednesday morning, The Fly reports. They currently have an outperform rating on

Cytokinetics (NASDAQ:CYTK) had its price objective boosted by Cantor Fitzgerald from $29.00 to $41.00 in a research note issued to investors on Wednesday morning, The Fly reports. Cantor Fitzgerald cu

BeiGene, a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion.

First Citizens Bank & Trust Co. lessened its stake in Cytokinetics, Inc. (NASDAQ:CYTK) by 29.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Excha

BidaskClub lowered shares of Cytokinetics (NASDAQ:CYTK) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday morning, BidAskClub reports. A number of other analys

Cytokinetics (NASDAQ:CYTK) had its target price upped by HC Wainwright from $35.00 to $38.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. The firm currently

Cytokinetics, Inc. (NASDAQ:CYTK)’s share price gapped down prior to trading on Friday after an insider sold shares in the company. The stock had previously closed at $27.79, but opened at $25.72. Cy